| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pluri Inc.$2.12
+0.02 (+1.19%)
D 27Pipeline Score Fair Value Biotech · Commercial
Market Cap
25.61 M
EPS
-2.87
P/E Ratio
-
Value Trade
7.20 K
SEC Financials
Q1 2026Dilution Risk
Revenue
167.00 K
R&D Expenses
3.96 M
Total Assets
26.06 M
Total Liabilities
26.06 M
Equity
-18.60 M
D/E Ratio
12,345
-28.28 %
Week
-29.35 %
1 Month
-35.31 %
3 Month
-40.5 %
6 Month
-92.54 %
5 Year
-99.85 %
All Time
Cash Data
Cash Position
3.42 M
Monthly Burn
2.18 M
Runway
0.5 mo
Burn Trend
StableSEC Filing
May 14, 2026
Overview
Volume
991.00
52 Week Range
2.22 - 5.96
% held by Insiders
42.59 %
% held by Institutions
12.67 %
Enterprise Value
55.30 M
Total Shares
10.05 M
Short %
0.29 %
Float Shares
6.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D27
Pipeline Score $7M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.9x
rNPV / MCap Top 29%
Micro Cap (rank 644 of 905)
Percentile RankPluri Inc. faces pipeline headwinds (27/100), with $1.4B risk-adjusted pipeline value, led by PLX-PAD in Hip Fracture (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX-PAD Small molecule | Hip Fracture | Phase 3 | NCT03451916 | 64% | $1.1B | COMPLETED | 240 | - | - | Sep 6, 2023 | - | Sep 28, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLUR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
PLUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PLUR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PLUR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PLURPluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership
Pluristyx has received a Notice of Allowance from the Japanese Patent Office for its innovative synthetic mRNA technology, which enhances protein expression and stabilizes mRNA. This advancement is crucial for the commercialization of induced pluripotent stem cell (iPSC) therapies in Japan, a leader in regenerative medicine. The technology streamlines the reprogramming process, significantly reducing production time for clinical-grade iPSCs.
Read more →PLURPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Inc. has announced the completion of U.S. cosmetic product listings for its regenerative aesthetic products, Regenativo+ and Placento+, through its subsidiary Cellav. The company is preparing for a commercial launch in the U.S. market, which is projected to grow significantly. Clinical validation supports the efficacy of the products, and discussions with distributors are underway. However, the products are not FDA approved and face regulatory requirements.
Read more →PLURPluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
Pluri Inc. announced that Alejandro Weinstein, its Chairman, has made an additional $2.5 million investment at a 30% premium to market price. This follows a previous investment and highlights Weinstein's continued support for the company's growth strategy. The funds from this private placement, amounting to approximately $2.5 million, will be used for general working capital. The transaction involves the sale of common shares and warrants, with an emphasis on enhancing shareholder value through focused execution.
Read more →PLURPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
Pluri Inc. has been granted a patent by the China National Intellectual Property Administration for its 3D immune cell expansion and activation technology. This patent complements previously secured patents in the U.S., Japan, Korea, Australia, and Israel, strengthening Pluri's global intellectual property portfolio. The technology enables scalable and automated manufacturing of diverse immune cell therapies, positioning Pluri to capitalize on the rapidly growing cell therapy market in China. This strategic expansion is expected to support cross-border partnerships and global collaborations, contributing to the company's efforts in enhancing cost-efficiency and maintaining quality control in cell production.
Read more →PLURPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
Pluri, Inc. has announced the successful completion of the first phase of its program with Resbiomed Technologies, focusing on the production of placenta-derived biomaterials. The collaboration leverages Pluri's proprietary bioprocessing expertise to enhance the quality and scalability of these materials for use in regenerative medicine. Both companies are now prepared to advance to the next phase of the project, which aims to refine manufacturing processes and ensure consistent quality. This milestone underscores the increasing demand for PluriCDMO services in the biotech sector.
Read more →PLURPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
Pluri, Inc. has expanded its collaboration with Remedy Cell Ltd. by successfully implementing clinical-grade manufacturing processes at Pluri's GMP facility. This achievement includes the completion of engineering runs and the production of clinical-grade batches for Remedy Cell's initial Phase 1b clinical trial, marking significant progress in developing secretome-based therapies for fibrotic diseases. Both companies expressed optimism about their partnership as they aim to provide innovative biotherapeutic solutions to address unmet medical needs.
Read more →PLURPluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Pluri Inc. has appointed Alejandro Weinstein as the new Chairman of the Board, signaling a strategic shift aimed at unlocking value within the company. Weinstein, one of Pluri's largest shareholders, plans to enhance market positioning and realize the potential of Pluri's assets. As part of the leadership transition, outgoing Chairman Zami Aberman will move to the role of Vice Chairman. Additionally, Pluri has entered a private placement agreement to raise approximately $2.5 million to support its operations.
Read more →PLURPluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
Pluri Inc. has received multiple industry honors, including the title of Overall BioAgriculture Company of the Year from the Biotech Breakthrough Awards. Additionally, its subsidiaries Coffeesai Ltd. and Kokomodo Ltd. garnered significant recognition for innovations in sustainable food production and cellular agriculture technology, respectively. Pluri's CEO, Yaky Yanay, is set to accept the 2024 Egalitarian Employment Award on behalf of the company. These accolades highlight Pluri's strong position in the biotechnology sector and its commitment to developing impactful cell-based solutions.
Read more →PLURPluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a wholly-owned subsidiary focused on regenerative skincare, following a partnership with Miss Universe Skincare. This collaboration aims to co-develop advanced skincare products utilizing Pluri's proprietary 3D cell expansion technology and is expected to launch its first product in 2026. The partnership is set to leverage Miss Universe Skincare's global distribution network, reaching a market projected to grow significantly in the coming years. This move aligns with Pluri's strategy to expand into high-demand, revenue-generating markets.
Read more →PLURPluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Pluri Inc. has reported significant growth in revenue, with nearly 400% increase in the first nine months of fiscal year 2025 compared to the previous year. The company is strategically entering the cultivated cacao and coffee markets, addressing global supply challenges. Additionally, Pluri is pursuing partnerships and has received further funding to support its initiatives in healthcare and AgTech. The CEO's letter emphasizes continued expansion efforts and the potential of its proprietary cell expansion technology.
Read more →PLURPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Pluri Inc. has completed the acquisition of approximately 71% of Kokomodo Ltd., a cultivated cacao AgFoodTech company, for $4.5 million. Kokomodo will operate independently under its current leadership while benefiting from Pluri's resources. This acquisition aims to enhance innovation in sustainable cacao production and address climate change impacts on traditional farming.
Read more →PLURPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
Pluri Inc. has announced the granting of two patents for its immune cell expansion technologies in the U.S. and Israel. These patents focus on MAIT cells, which are crucial for treating solid tumors. The company aims to leverage its proprietary 3D cell expansion technology to enhance the scalability and efficacy of these immune cells for potential immunotherapy applications. This development positions Pluri favorably in the growing field of cancer treatment.
Read more →PLURLEAK OUT AGREEMENT This Leak Out Agreement (the " Leak-Out Agreement " or the " Agreement ") is made and entered into as of _______, 2025, between Pluri, Inc., a Nevada corporation whose address is ________________ (the
Pluri, Inc. has entered into a Leak-Out Agreement with a Holder, allowing the sale of shares under specific restrictions. The agreement permits the Holder to transfer a limited percentage of shares based on trading volume on either Nasdaq or the Tel Aviv Stock Exchange during a predefined Leak-Out Period. However, the transfer rights are contingent on compliance with certain obligations; failure to abide could trigger a Breach Event and terminate the agreement. The terms are governed by Israeli law and include multiple stipulations regarding the sale and registration of the shares.
Read more →PLURPluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
Pluri Inc. has entered an exclusive collaboration with Hemafund to enhance Ukraine's preparedness for radiation emergencies. The partnership aims to stockpile and distribute PLX-R18, a cell therapy for Hematopoietic Acute Radiation Syndrome (H-ARS). The agreement is set for an initial three-year term, focusing on building capacity for 12,000 doses. This initiative responds to recent escalations in regional nuclear threats.
Read more →PLURPluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
Pluri Inc. announced a $3.5 million private placement from Merchant Adventure Fund, raising total recent financings to $10 million. The investment reflects strong confidence in Pluri's technology and strategy. The funds will support the company's growth in cell-based technology across various sectors, including pharma and foodtech.
Read more →PLURPluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
Pluri Inc. has announced a strategic investment of $6.5 million led by Alejandro Weinstein, who will join the Board of Directors. Concurrently, Pluri is acquiring a 71% stake in Kokomodo Ltd. for $4.5 million, enhancing its position in sustainable food technologies. These transactions aim to strengthen Pluri's financial foundation and expand into the cultivated cacao market, which is projected to grow significantly by 2030.
Read more →PLURPluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Pluri Inc. congratulated Mesoblast on the FDA's approval of the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease. This milestone is seen as significant not just for Mesoblast but for the entire cellular medicine field, highlighting the potential of MSC therapies. Pluri's CEO expressed optimism about the future of regenerative medicine, emphasizing its capacity to address root causes of diseases for better patient outcomes. Pluri continues to leverage its proprietary technology in developing next-generation cell-based therapies.
Read more →PLURPluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025
Pluri Inc. has been shortlisted for the CDMO of the Year Award at the Advanced Therapies Awards 2025, only months after launching its CDMO division. The company, which specializes in cell-based solutions, is recognized for its advancements and contributions to transformative therapies. CEO Yaky Yanay highlighted the success of the division in establishing partnerships and client agreements. Pluri's cutting-edge technology, particularly its 3D cell expansion system, positions it well in the biotech industry.
Read more →PLURPluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
Pluri Inc. is assessing its readiness to mass-produce PLX-R18, a potential treatment for acute radiation syndrome (H-ARS), due to escalating global nuclear threat concerns. The treatment has shown promising results in improving survival and recovery in various studies. Pluri is evaluating production scalability in anticipation of increased demand and has emphasized its commitment to support communities in emergencies. However, the company's future projections are subject to regulatory approval and various operational uncertainties.
Read more →PLURPluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
Pluri Inc. announced a collaboration with Bar-Ilan University, funded by the Israel Innovation Authority, to enhance its MAIT Cell Therapy for solid tumors. Led by Professor Cyrille Cohen, this partnership aims to improve the efficacy and tumor specificity of CAR-MAIT cells using novel Siglec-based Chimeric Switch Receptors. MAIT cells, known for their unique targeting properties and low risk of Graft versus Host Disease, present a promising solution for solid tumors. The collaboration seeks to advance innovative allogeneic cell therapies towards preclinical studies.
Read more →PLURPluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. has entered into a manufacturing agreement with Kadimastem Ltd. to produce two novel cell therapy product candidates: AstroRx for ALS and IsletRx for diabetes. This partnership will leverage PluriCDMO's expertise and state-of-the-art GMP facility, providing crucial support as Kadimastem prepares for clinical trials. Executives from both companies expressed optimism about the collaboration, highlighting its importance for improving patient care.
Read more →PLURPluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
Pluri Inc. has announced a €1 million proof of concept agreement with an international agriculture corporation aimed at improving global vegetable supply. The collaboration will leverage Pluri's cell-expansion technologies alongside the partner's expertise in the food industry. This venture is expected to reduce environmental impact and contribute to greater food security while aligning with the increasing demand from a growing global population. The market for vegetable farming is also anticipated to see significant growth in the coming years.
Read more →PLURPluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
Pluri Inc. announced that its subsidiary, Ever After Foods, secured a $10 million strategic investment aimed at enhancing the scalability of cultivated food production. The investment will empower Ever After Foods to leverage Pluri's advanced production technology, enabling significant cost reductions and increased productivity. The funding round was led by global corporates with experience in the food technology sector, highlighting confidence in the company's innovative solutions. With this support, Ever After Foods plans to expand its market presence and improve supply chain efficiencies in the cultivated meat space.
Read more →PLURPluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
Pluri Inc. (Nasdaq:PLUR) has announced that its leadership will be participating in various international conferences, showcasing its advancements in cell-based technologies. Notably, the company is set to present its innovative coffee cultivation methods and discuss its PLX-PAD therapy for knee osteoarthritis. The upcoming conferences, such as MIW and ATiO, will feature presentations from key executives including CEO Yaky Yanay. Amid these developments, Pluri's technologies continue to target sustainability and health improvements, though the company faces potential regulatory and market challenges.
Read more →PLURPluri Inc. Announces 1-for-8 Reverse Share Split
Pluri Inc. has announced a 1-for-8 reverse share split, set to take effect at market open on April 1, 2024. This adjustment will reduce the number of outstanding common shares from approximately 41.8 million to 5.2 million. The move, approved by the Board of Directors, is intended to streamline the company's capital structure without affecting shareholder ownership percentages significantly. The change complies with Nevada law, and Equiniti Trust Company, LLC will serve as the exchange agent for the split.
Read more →PLURPluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
Pluri Inc. has announced the launch of its innovative cell-based coffee, designed to tackle the price volatility challenges highlighted in the International Coffee Organization's 2024 Market Report. The report emphasized that adverse weather conditions are negatively impacting coffee supply stability. Pluri's method of lab-based coffee production aims to eliminate environmental factors affecting traditional coffee cultivation, ensuring more consistent availability and sustainability. The company claims that their process could significantly reduce resource consumption in comparison to conventional farming practices.
Read more →PLURPluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
Pluri Inc. has been selected by Remedy Cell Ltd as the contract development and manufacturing organization (CDMO) for its drug RC-0315, aimed at treating Idiopathic Pulmonary Fibrosis (IPF). The agreement entails the production of clinical-grade materials required for the Phase Ib clinical trial of RC-0315. Remedy Cell's CEO expressed optimism about the collaboration, highlighting the unmet need in IPF treatment. The partnership is expected to leverage Pluri's advanced manufacturing capabilities to expedite the drug’s development process.
Read more →PLURPluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
Pluri Inc. has announced the approval of its first patent for a 3D bioreactor technology designed for plant cell cultivation. This innovation allows for efficient production of plant cells with applications in sustainable agriculture and healthcare. The 3D cell expansion technology notably enables the production of cell-based coffee using considerably less water and land area. Pluri's growth potential is underscored by the projected expansion of the cellular agriculture market from $133 billion in 2021 to $515 billion by 2030.
Read more →PLURPluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
Pluri Inc. has appointed Jim Roosevelt, Jr. to its Advisory Board, bringing valuable expertise in healthcare and public policy. Roosevelt's past leadership at Tufts Health Plan and advocacy for equitable healthcare access aligns with Pluri's mission of developing innovative cell-based treatments. His contributions will focus on strategic growth plans, particularly in regenerative medicine, and enhancing relationships with investors and government agencies. This appointment aligns with the company's efforts to address unmet medical needs and improve personalized therapies.
Read more →PLURPluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
Pluri Inc. has announced significant advancements and new business verticals, including PluriAgtech and PluriCDMO, as part of its strategic growth for 2024. The company has secured partnerships and contracts, such as a notable $4.2 million agreement with the U.S. NIH for the development of a treatment for acute radiation syndrome. Additionally, Pluri has launched a cell-based coffee business aimed at addressing sustainability challenges in the coffee industry. CEO Yaky Yanay emphasized the company's commitment to innovation and building a robust pipeline of products.
Read more →PLURPluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Pluri Inc. has launched PluriCDMO™, a new Contract Development and Manufacturing Organization division focused on manufacturing cell-based therapies. This initiative aims to leverage Pluri's two decades of experience and advanced technology to provide comprehensive manufacturing solutions across all development phases. The new division will enhance the company's ability to support innovative therapies in the growing cell and gene therapy market. Andy Lewin, with extensive CDMO leadership experience, will lead this initiative, which is expected to boost revenues and streamline operations.
Read more →PLURPluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
Pluri Inc. has entered into an agreement with Bar-Ilan University to develop PLX cells aimed at treating cocaine addiction, following promising pre-clinical results. The PLX-PAD cells showed effectiveness in reducing cocaine cravings and increasing neurogenesis in animal models, which could provide a novel, one-time treatment option. Under the terms of the agreement, Bar-Ilan will commercialize the product while Pluri retains a 20% share in future revenue. This partnership addresses a critical need for effective treatments for cocaine addiction, a growing concern in the U.S. and Europe.
Read more →PLURPluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
Pluri Inc. announced the successful results of a Phase I study published in Nature Bone Marrow Transplantation, where their cell therapy PLX-R18 increased blood cell counts in patients and reduced the need for transfusions. The study focused on patients with incomplete hematopoietic recovery after hematopoietic cell transplantation. PLX-R18 demonstrated a favorable safety profile with well-tolerated administration and lasting effects for up to 12 months. Additionally, it has received Orphan Drug Designation from the FDA for multiple treatments including acute radiation syndrome.
Read more →PLURPluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
Pluri Inc. has appointed Lorne Abony to its Board of Directors, effective July 11, 2023. Abony is recognized for his experience in scaling businesses and investments in cellular agriculture. His insight is expected to enhance Pluri’s strategic growth, particularly in cultivated foods. The leadership believes that Abony's involvement will bolster the company's potential in utilizing its cell-expansion technology.
Read more →PLURPluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept Milestones over the last year include launch of new Company strategy, j
Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept HAIFA, Israel, December 22, 2022 - Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Plurist
Read more →PLURPluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
HAIFA, Israel, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company, announced today that it has signed securities purchase agreements with domestic and non-U.S. investors for the sale of an aggregate
Read more →PLURPluri wins BioTech Breakthrough Cell Innovation of the Year Award
HAIFA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company” (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, won Cell Innovation award in the Cell Biology category of the second annual BioTech
Read more →PLURPluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences. Conference: CPHI
Read more →PLURPluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates New company strategy will reduce cash burn by approximately 30%, with $56M in cash
CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates Israel, September 29, 2022 - Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a
Read more →PLURPluri CEO Issues Shareholder Update
Pluri CEO Issues Shareholder Update HAIFA, Israel, July 25, 2022 - Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Exe
Read more →PLURPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
As of July 26, 2022, Pluri’s stock will trade under the symbol PLUR The new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting gl
Read more →PLURPluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, July 1
Read more →PLURPluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (
Read more →PLURPluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients. PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile. PL
Read more →PLURPluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today jointly announced the appointment of Eyal Ro
Read more →PLURPluristem CEO Issues Shareholder Update
HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. As I look ahead, I am more confident
Read more →PLURPluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food tech Pluristem and Tnuva are proven pioneers in cell culture technology and consumer food branding, with 100+ y
Read more →PLURPluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated Israel, Dec 27, 2021 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the "Company"), a leading biotechnology company, today announced topline results from its Phase II
Read more →PLURPluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on muscle regeneration following hip fracture surgery on November 22 at 9:15am EST HAI
Read more →PLURPluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform
HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an additional grant from the Israel Innovation Authority (IIA) to support research based on i
Read more →PLURPluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the T
Read more →PLURPluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel Topline results are expected during the fourth quarter of 2021 HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TA
Read more →PLURPluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement Offer” in the amount of €20 million (approximately $24 million) from the European
Read more →PLURPluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatments The company will conduct an analyst and investor call on May 3, 2021, at 10am EDT HAIFA, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- Plur
Read more →PLURPluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products (“Pluristem” or the “Company”), today announced it has entered into defin
Read more →PLURPluristem Announces Uplisting to the Nasdaq Global Market
HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced that effective as of market open on January 29, 2021, its comm
Read more →PLURPluristem Announces Appointments of Two Directors to Board
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, is pleased to announce the appointment of Ms. Maital Shemesh-Rasmussen,
Read more →PLURPluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has entered into a collaboration agreement with Mexic
Read more →PLURPluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the study to meet its primary endpoint PLX-PAD was well tolerated, and no safety co
Read more →PLURDecember 9 , 2020 PLURISTEM CONFERENCE CALL Inspired by Life 2 This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Fede
December 9 , 2020 PLURISTEM CONFERENCE CALL Inspired by Life 2 This presentation contains express or implied forward - looking statements within the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws . For example, we are using forward - l
Read more →PLURPluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohort PLX-R18 was found to be safe and well-tolerated Topline results from the full Phase I clinical trial expected in Q1 2021 (n=21) HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -
Read more →PLURPluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
HAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced that it has received clearance from the safety committee of an inves
Read more →PLURPluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has received approval from the Israeli Ministry
Read more →PLURPluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the U.S. Food and Drug Administration (FDA) has cle
Read more →PLURPluristem Announces End of Patient Enrollment in its Phase I Hematology Study
HAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has completed patient enrollment in its Phase I study
Read more →PLURPluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today its subsidiary, Pluristem Ltd., has signed a non-binding
Read more →PLURPluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
HAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that Germany’s health regulatory agency, the Paul Ehrlic
Read more →PLURPluristem CEO Issues Shareholder Update on Clinical Programs
CEO Issues Shareholder Update on Clinical Programs Israel, July 21, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chie
Read more →PLURPluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today the activation of clinical sites and initiation of enrol
Read more →PLURPluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
Collaboration will enable Pluristem to develop new technologies relying on its PLX platform The consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program, and includes industry and academic leaders in AI and genome editing HAIFA, Israel,
Read more →PLURPluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells 75% of patients no longer in need of any mechanical ventilation 62.5% of the patients discharged alive from the hospital A 28-day study period is also the primary endpoint timeline for P
Read more →PLURPluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has entered into definitive agreements with two i
Read more →PLURPluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
• Elaborating on agreement terms and tranches schedule • Provides update on cash position and clinical program HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading regenerative medicine company develo
Read more →PLURNASDAQ / TASE :NNDM www.nano-di.com | 2020 Nano Dimension. All rights reserved. Nano Dimension is a Developer & Provider of Intelligent Machines and ConsumableConductive&DielectricMaterials(Inks)fortheFabricationof Addit
ENVIRONMENTAL Limits environmental impact through optimized design, size, weight. Reduces waste with additive manufacturing capabilities. COMPLEX GEOMETRIES CONFIDENTIALITY Enables retention of sensitive IP in-house during development. Eliminates concerns and costs related to IP
Read more →PLURPluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies
HAIFA, Israel, April 24, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the European Investment Bank (“EIB”) has approved
Read more →PLURPluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP) Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of complications associated with COVID-19 HAIFA, Israel, April 13, 2020 (GLOBE NEWSWIRE)
Read more →PLURPluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure All treated patients were in Intensive Care Units (ICU) on ventilators and suffered f
Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure Israel, April 7, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel bio
Read more →PLURPluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use
Expects to treat more patients in Israel in the coming days Company is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a l
Read more →PLURPluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity
Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity March 26, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biolo
Read more →PLURPluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced it received a response to the proposal it submitted to the U.S. Bio
Read more →PLURPluristem Therapeutics CEO Issues Shareholder Update
HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products, today issued an update to its shareholders from its Chief Executive Officer and Pr
Read more →PLURPluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study
HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has enrolled 75% of the 246 patients planned for its Phas
Read more →PLURPluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment
HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has completed enrollment of 50% of the 240 patients plann
Read more →PLURPluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs
PLX-R18 is currently in development as a countermeasure for acute radiation syndrome and as a treatment for incomplete recovery following hematopoietic cell transplantation Data from 1st and 2nd cohorts of hematological study showed PLX-R18 was safe and well tolerated and led to
Read more →PLURPluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs
HAIFA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced additional information relating to its live Key Opinion Leader (KOL) call regarding its
Read more →PLURPluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key Opinion Leader (KOL) call o
Read more →PLURPluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineages Data is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA, Israel, July 31, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PST
Read more →PLURPluristem Therapeutics’ CEO Issues Shareholders Update
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky
Read more →PLURPluristem Announces One-for-Ten Reverse Split of its Common Shares
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that, its Board of Directors has approved a 1-for-10 reverse spli
Read more →PLURPluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel p
Read more →PLURPluristem Therapeutics' CEO Issues Shareholder Letter
Therapeutics' CEO Issues Shareholder Letter HAIFA, Israel, July 2, 2019 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its C
Read more →PLURPluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the completion of the transition period of its Co-CEO structure a
Read more →PLURPluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
HAIFA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has developed a serum-free formulation to support the
Read more →PLURPluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional patent application titled “Me
Read more →PLURPluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
HAIFA, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant milestone in its ongoing
Read more →PLURPluristem Therapeutics Issues Shareholder Update
Recent financing provides funding through multiple potentially value-creating milestones Providing short and mid-term milestones, targeting marketing and significant contracts HAIFA, Israel, April 23, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI
Read more →PLURPluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
HAIFA, Isreal, April 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today the pricing of an underwr
Read more →PLURPluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock
HAIFA, Israel, April 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today that it intends to offer a
Read more →PLURPluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18
HAIFA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled the second cohort of six pat
Read more →PLURPluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions
HAIFA, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company and NASA’s Ames Research Cent
Read more →PLURPluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries
Project was awarded Joint Grant by the Israeli Ministry of Defense and the Israel Innovation Authority HAIFA, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based
Read more →PLURPluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient
Buerger’s disease is a severe vascular inflammatory disease associated with high risk of amputation Patient was at a pre-amputation stage and was treated with PLX-PAD cell therapy under compassionate use treatment After a 12 month follow up period, PLX-PAD restored peripheral b
Read more →PLURPluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome
HAIFA, Israel, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting with the U.S. Food and Drug A
Read more →PLURPluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)
HAIFA, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader (KOL) breakfast meeting on perip
Read more →PLURPluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
HAIFA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has entered into a license agreement with a subsidiary of
Read more →PLURPluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting
Primary safety endpoint met in first cohort with early signals of efficacy in improving blood counts Trial is progressing with enrollment in the second cohort currently underway HAIFA, Israel, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PST
Read more →PLURPluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematology’s (ASH) Annual Meeting
Clinical data from the first cohort of Phase I study for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation Program was granted an FDA Orphan Drug Designation HAIFA, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics In
Read more →PLURPluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update
HAIFA, Israel, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended Septembe
Read more →PLURPluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions
The Company will also present at the BioEurope, Annual Vascular Interventional Advances and Cell and Gene Therapy Manufacturing conferences, all held in November HAIFA, Israel, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading reg
Read more →PLURPluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study
PLX-PAD cells Demonstrated a Significant Increase in Muscle Volume and Strength First Allogeneic Cell Therapy Study to Successfully Show the Potential of Treating Patients with Skeletal Muscle Injury Ongoing Phase 3 Hip Fracture study in U.S. and Israel Cleared to Enroll Additi
Read more →PLURPluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update
HAIFA, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fourth quarter and fiscal year ended Ju
Read more →PLURPluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation
HAIFA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration (FDA) has granted Orp
Read more →PLURPluristem Initiates Two Pivotal Phase III Studies in Israel
HAIFA, Israel, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared the Company to commence patient recruitment in Israel
Read more →PLURPluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure
Patent covers PLX-R18’s protection of the gastrointestinal (GI) tract from radiation exposure Recent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the recovery of the GI tract after radiation exposure HAIFA, Israel, July 26, 20
Read more →PLURPluristem Signs Collaboration Agreement With Thermo Fisher Scientific
HAIFA, Israel, July 09, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundame
Read more →PLURPluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure
HAIFA, Israel, June 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported positive data from studies conducted in collaboration with Fukushima Medical University evaluating P
Read more →PLURPluristem to Open Weekly Market Trading at TASE Following Positive Study Results
HAIFA, Israel, June 14, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, is delighted to announce that it has been invited by the Tel Aviv Stock Exchange (TASE) to open the weekly trading
Read more →PLURPluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI) HAIFA, Israel, June 12, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PS
Read more →PLURPluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018
HAIFA, Israel, June 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells i
Read more →PLURPluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights
HAIFA, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results and corporate developments for its third quarter of fiscal 2018 ended March 31, 201
Read more →PLURPluristem and Indiana University to Initiate Joint Project Evaluating PLX-R18 in Acute Radiation Syndrome, Targeting Bridging Data for Pivotal Study
The 5-year joint project was granted $2.5 million from the U.S. National Institutes of Health (NIH) Data from these studies will support BLA filing for marketing approval of PLX-R18 in the treatment of ARS HAIFA, Israel, April 23, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutic
Read more →PLURPluristem’s PLX-R18 Improves Hematopoietic Transplantation as Reported in Scientific Journal Frontiers in Medicine
HAIFA, Israel, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Frontiers in Medicine has published key findings from a study of PLX-R18 that demonstrate the
Read more →PLURPluristem Issues Letter to Shareholders
HAIFA, Israel, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results for the second quarter of fiscal 2018 ended December 31, 2017 and issued a letter
Read more →PLURPluristem’s PLX Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study
PLX cells exhibit anti-proliferative effect on a wide range of human cancer cell types Pre-clinical study results show statistically significant reduction in tumor size as well as complete tumor remission in 30% of treated recipients HAIFA, Israel, Jan. 12, 2018 (GLOBE NEWSWIRE
Read more →PLURPluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
Authorization is also under the provision of the Conformity Assessment and Acceptance of Industrial Products (CAA) agreement between Israel and the European Union (EU), which will serve to qualify Pluristem’s facilities for future marketing in the EU as well. HAIFA, Israel, Dec.
Read more →PLURPluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
Data from Phase II-equivalent study demonstrated improved survival and hematological recovery of non-human primates (NHP) exposed to high levels of radiation PLX-R18 cells are in late-stage development as a treatment for ARS, supported by the U.S. National Institutes of Health (
Read more →PLURPluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
Patent relates to the use of Mesenchymal Stem Cells (MSCs) for muscle regeneration following muscle injury Pivotal Phase III study to take place in U.S. and Europe to support recovery from hip fracture HAIFA, Israel, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
Read more →PLURPluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
HAIFA, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results and corporate developments for its first quarter of fiscal 2018 ended September 30
Read more →PLURPluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD
Tel Aviv Sourasky Medical Center will act as the sponsor of the study PLX-PAD cells have demonstrated efficacy in preclinical models of GvHD HAIFA, Israel, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-b
Read more →PLURPluristem Announces Pricing of Public Offering of Common Stock on the Tel Aviv Stock Exchange
HAIFA, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PLTR) announced today the pricing of its previously announced public offering of 9,000,000 shares of common stock on the Tel Aviv Stock Exchange (TASE) at a price of $1.67 (NIS 5.90)
Read more →PLURPluristem Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors Tender
HAIFA, Israel, Oct. 29, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQCM:PSTI) (TASE:PLTR) announced today that in connection with its proposed public offering of its shares of Common Stock on the Tel Aviv Stock Exchange (TASE) it has concluded an Israeli institutio
Read more →PLURPluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases
HAIFA, Israel, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the European Patent Office has issued the company a patent titled, “Methods for Treating Radia
Read more →PLURPluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
Trial was recently awarded $8.7 million grant from the European Horizon 2020 program Pluristem plans to use results of trial to achieve marketing approval in both the U.S. and Europe HAIFA, Israel, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TA
Read more →PLURPluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration
HAIFA, Israel, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the company has been issued two new patents by Hong Kong Patents Registry for its cell therap
Read more →PLURPluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights
Company steps up its clinical platform with pipeline of three late-stage clinical indications All late-stage programs are supported and funded by 3rd parties with over $19 million in non-dilutive funding awarded to PLX programs PLX-R18 advances towards pivotal trial in Acute Ra
Read more →PLURPluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017
Austria’s regulatory health agency clears CLI study and joins the U.S., U.K., and Germany in conducting the 250-patient Phase III trial HAIFA, Israel, July 10, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based c
Read more →PLURPluristem to Present New Data from ARS study at Radiology Conference in U.S.
HAIFA, Israel, June 29, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that new data from its non-human primates (NHP) pilot study evaluating PLX-R18 as a treatment for A
Read more →PLURPluristem Provides Shareholder Update on Corporate and Clinical Developments
HAIFA, Israel, May 22, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results and corporate and clinical developments for the third quarter of fiscal 2017 ended
Read more →PLURPluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
All PLX-treated groups showed improvements in survival rates compared to untreated groups PLX-R18 cells did not increase leukocyte levels in non-irradiated NHPs, indicating no requirement to determine levels of radiation exposure prior to administration Data will inform a pivot
Read more →PLURPluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets
In addition, Pluristem has over 110 pending patent applications. The patents portfolio covers over 30 different innovations across major markets. HAIFA, Israel, April 19, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI), (TASE:PSTI), a leading developer of pla
Read more →PLURPluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan
HAIFA, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI), (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced advancement in discussions with Sosei Corporate Venture Capital Ltd. (Sosei CVC) towards establis
Read more →PLURPluristem Launches Co-CEO Structure and Appoints New CFO
Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman Erez Egozi appointed as Chief Financial Officer HAIFA, Israel, March 29, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI), (TASE:PSTI), a leading dev
Read more →PLURPluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
HAIFA, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments for the second quarter of fiscal 2017, ende
Read more →PLURPluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option
HAIFA, Israel, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that H.C. Wainwright & Co., LLC, the sole book-running manager of its previously announced bought offering of 12,244,898 shares of common stock and warrants to p
Read more →PLURPluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000
HAIFA, Israel, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI) announced today that due to increased demand, it has entered into an amended and restated underwriting agreement (as amended and restated, the “Underwriting Agreement”) with H.C
Read more →PLURPluristem Announces Bought Deal Offering
HAIFA, Israel, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC, under which the underwriter has agreed to purchase on a firm commitment basis
Read more →PLURPluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
PLX-PAD cells could potentially obtain early conditional marketing approval in Europe via the Adaptive Pathways pilot project based on positive interim efficacy data from first 125 patients This approval joins those from the U.S. FDA and U.K. for this 250-patient Phase III Trial
Read more →PLURPluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
Top line results from the 172-patient trial to be reported in early 2018 Data to support Pluristem’s planned Biologics License Application for marketing approval of PLX-PAD in the U.S. and Europe 14 million people in the U.S. are treated for IC, at a cost of approximately $2.5
Read more →PLURPluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA
HAIFA, Israel, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the Company’s Phase III study of its PLX-PAD cells in the treatment of critical limb ischemia
Read more →PLURPluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD
Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation (BIRD) to fund the research Constitutes a 3rd potential hematologic indication f
Read more →PLURPluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy
HAIFA, Israel, Dec. 23, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that following the recently adopted Chinese policy relating to outbound investments by Chinese comp
Read more →PLURPluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
Pluristem and Sosei CVC will establish a new corporation which will pursue the clinical development and commercialization of PLX-PAD in Japan The first indication to be developed will be Critical Limb Ischemia (CLI) Japan’s regulatory agency has already agreed on the study desi
Read more →PLURPluristem’s PLX-R18 Advances into Second Cohort of Dose Selection Study for Treatment of Acute Radiation Syndrome
NIH’s NIAID completes first cohort of dose selection study Data from completed study expected in first half of 2017 Upon determining the optimal dose, a pivotal trial could be conducted to support marketing authorization of PLX-R18 for ARS under the FDA Animal Rule regulatory p
Read more →PLURPluristem Reports First Quarter Fiscal 2017 Corporate and Financial Highlights
$30 million equity investment term sheet signed with large Chinese investment fund active in the healthcare industry Significant advancement towards initiation of pivotal Phase III trials U.S. FDA provided positive feedback and UK’s MHRA approved initiation of the multinational
Read more →PLURPluristem’s $30 Million Equity Funding Approved by Innovative Medical Management Co.’s Shareholders
Term sheet for investment at $1.77 per share is now binding Innovative Medical is a publicly listed Chinese company active in the healthcare industry, and is an affiliate of ZSVC, one of the largest technology-focused VC firms in China HAIFA, Israel, Nov. 10, 2016 (GLOBE NEWSWI
Read more →PLURPluristem Continues to Strengthen its Position in China and Receives Key Cell Therapy Patent
Patent addresses methods of treating Ischemic conditions such as CLI using placental cells HAIFA, Israel, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that th
Read more →PLURPluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency
Pluristem expects to begin patient enrollment in the UK in first half of 2017 The trial will recruit in the U.S. and EU HAIFA, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy pro
Read more →PLURPluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a Leading Institutional Life Sciences Fund
Innovative Medical is a publicly listed Chinese Company active in the healthcare industry, and is an affiliate of ZSVC, one of the largest technology-focused VC firms in China Funds to support late-stage pivotal trials for Pluristem’s cell therapies Shares will be sold at $1.77
Read more →PLURPluristem CEO Zami Aberman Re-Elected to Alliance for Regenerative Medicine’s Board of Directors
HAIFA, Israel, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced its Chairman and CEO, Zami Aberman, has been re-elected as Member of the Board of Directors of the
Read more →PLURPluristem Advances Towards U.S. Clinical Trial in PLX-R18 and Announces Principal Investigator
Dr. Hillard Lazarus of Case Western Reserve University will be the Principal Investigator of the trial The trial protocol was cleared by the U.S. FDA Incomplete engraftment after HCT is one of several hematologic indications to be targeted by PLX-R18 HAIFA, Israel, Sept. 14, 2
Read more →PLURPluristem Provides Fiscal Year 2016 Corporate and Financial Highlights
Executing an efficient commercialization strategy with three planned late stage pivotal trials Innovative regulatory pathway clearances including EU adaptive pathway and Japanese accelerated pathway for regenerative medicine, allowing early marketing access FDA clearance grante
Read more →PLURPluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular Medicine
The company will present the upcoming Phase III trial in CLI patients to Europe’s medical and scientific community Pluristem is meeting with clinical investigators who will take part in the upcoming trial HAIFA, Israel, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics
Read more →PLURPluristem’s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe’s Horizon 2020 Program
The study will enroll about 250 patients in Europe and the U.S. The grant will cover a significant portion of the study expenses PLX-PAD was previously selected by the EMA to be developed via the Adaptive Pathways project HAIFA, Israel, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Pluris
Read more →PLURPluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia
CLI is a severe unmet medical need whose treatment addresses a $12 billion global market Multinational study to be conducted in U.S. and Europe Estimated trial enrollment of approximately 250 patients Primary endpoint for BLA will be time to amputation and death HAIFA, Israel
Read more →PLURPluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip Fracture
Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDA Pluristem has already submitted the protocol to the European Medicines Agency for a single pivo
Read more →PLURPluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID
HAIFA, Israel, July 20, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced its participation in the Radiation Injury Treatment Network’s meeting titled, “Medical Management o
Read more →PLURPluristem Advances its U.S. FDA Trial in Hematologic Indication
Enters into an agreement with a global drug development services company (CRO) Trial was cleared by U.S. FDA earlier this year Data could support use of Pluristem’s PLX-R18 in a broad range hematologic indications HAIFA, Israel, July 11, 2016 (GLOBE NEWSWIRE) -- Pluristem Ther
Read more →PLURPluristem Reports Data Showing PLX-PAD Cells Effective in Treating Duchenne Muscular Dystrophy
PLX-PAD cells increase regeneration of muscle tissue and reduce inflammation and cell death Pluristem donated cells for the studies performed in conjunction with ADI- the Association Duchenne Israel HAIFA, Israel, June 22, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (N
Read more →PLURPluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
Trial expands to randomize 20 more patients to receive two injections per patient Data release on track for 2017 HAIFA, Israel, May 16, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, t
Read more →PLURPluristem Reports Third Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
HAIFA, Israel, May 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its fiscal third quarter ended March 31, 2016, and provided clinical and cor
Read more →PLURPluristem Awarded $3.3 Million Grant by Israeli Government
HAIFA, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its wholly owned subsidiary, Pluristem Ltd., has been awarded 12.7 million New Israeli Shekels
Read more →PLURPluristem Enters into Licensing Agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to Acquire Rights for Placental Cell Therapy Patent for Variety of Ischemic Conditions including Heart Disease and Stroke
HAIFA, Israel, April 21, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company de
Read more →PLURPluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents
HAIFA, Israel, April 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the Japan Patent Office has granted the Company two key patents addressing: 1) Pluristem’s co
Read more →PLURPluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
HAIFA, Israel, Feb. 10, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today reported financial highlights for its second quarter ended December 31, 2015, and provided clinical and corpo
Read more →PLURPluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016
HAIFA, Israel, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Dr. Karine Kleinhaus, the Company’s Divisional VP, North America, will present at the Bio CEO
Read more →PLURPluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant
Phase I, open-label trial will allow for interim data analysis PLX-R18 could potentially treat a broad range of hematologic indications Pluristem will pursue early market access for PLX-R18 in the U.S. HAIFA, Israel, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc
Read more →PLURPluristem Reaches Agreement With Japan's PMDA on Protocol for Final Trial Targeting Market Entry Via Accelerated Pathway
The agreement is expected to accelerate discussions with potential Japanese partners The study will include 75 patients and a 9 month follow-up HAIFA, Israel, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placent
Read more →PLURPluristem to Present at Phacilitate Cell & Gene Therapy World Conference in Washington DC on January 25-26, 2016
HAIFA, Israel, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the Company’s President and COO Yaky Yanay will deliver two presentations at the 12th Annual P
Read more →PLURPluristem and United Therapeutics End Licensing Agreement; Report Positive Data in Pulmonary Arterial Hypertension
Clinical study is ongoing and encouraging data reported for the first cohort Pluristem regains full rights with benefit of human clinical data for the indication & IV administration of PLX cells HAIFA, Israel, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDA
Read more →PLURPluristem Signs MOU for Collaboration With Fukushima Medical University to Study PLX-R18 in Acute Radiation Syndrome
HAIFA, Israel, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has signed a Memorandum of Understanding (MOU) for a collaboration with Fukushima Medical U
Read more →PLURPluristem to Present at Global Scientific & Investment Conferences in December
HAIFA, Israel, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that members of its executive and scientific teams will present at the following conferences during
Read more →PLURPluristem to Present New Data on PLX-R18 at American Society of Hematology’s Annual Meeting
HAIFA, Israel, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Dr. Racheli Ofir, Vice President Research & Intellectual Property, will present new data on PL
Read more →PLURPluristem Provides Corporate and Financial Highlights for First Quarter of Its Fiscal Year
HAIFA, Israel, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, reported financial results for its fiscal first quarter ended September 30, 2015, and provided financial and corpor
Read more →PLURPluristem to Participate in Three European Life Sciences Conferences in November
HAIFA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Company executives will be participating in three upcoming conferences in Europe. Pluristem r
Read more →PLURPluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications
HAIFA, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced it has expanded its five-year Collaborative Research Agreement with the Berlin-Brandenburg Center f
Read more →PLURPluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine
HAIFA, Israel, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that its Chairman and CEO, Zami Aberman, has been elected to serve on the Board of Directors of t
Read more →PLURPluristem and NIAID Met With U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome
HAIFA, Israel, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Pluristem and the National Institute of Allergy and Infectious Diseases (NIAID), a part of
Read more →PLURPluristem Provides Corporate and Financial Highlights for Fiscal Year 2015
HAIFA, Israel, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, reported yesterday financial results for its fiscal year ended June 30, 2015, and provides corporate and financial
Read more →PLURPluristem Completed Successful Meeting With the U.S. FDA in Preparation for Filing an IND for PLX-R18 to Treat Incomplete Hematopoietic Recovery After Bone Marrow Transplantation
HAIFA, Israel, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has completed a successful meeting with the U.S. Food and Drug Administration (FDA) regardi
Read more →PLURPluristem President Yaky Yanay Elected as Co-Chairman of Israel Advanced Technology Industries
HAIFA, Israel, Sept. 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced its President and Chief Operating Officer, Yaky Yanay, has been elected as Co-Chairman of the large
Read more →PLURPluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
HAIFA, Israel, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S. Patent and Trademark Office has issued to the Company patent #9,096,827 titled "Adher
Read more →PLURPluristem in Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol in Critical Limb Ischemia
HAIFA, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has conducted detailed discussions with the European Adaptive Pathways Discussion Group reg
Read more →PLURPluristem Therapeutics Announces Pricing of Registered Direct Offering of Common Stock and Warrants
HAIFA, Israel, June 25, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common stock and warrants to purchase up to 4,080,000 shares of common stock at a comb
Read more →PLURPluristem Granted Australian Patent for 3D Cell Expansion Technology & Use of PLX Cells in Broad Range of Indications
HAIFA, Israel, June 24, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use T
Read more →PLURPluristem Awarded $2.9 Million Grant by Israeli Government
HAIFA, Israel, June 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its wholly owned subsidiary, Pluristem Ltd., has been awarded 11.1 million New Israeli Shekels
Read more →PLURPluristem Awarded Grant From Israel's Ministry of Economy for Marketing Its PLX Cell Therapy in Japan
HAIFA, Israel, June 3, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that it has been awarded a Smart Money grant from Israel's Ministry of Economy. The program's aim is
Read more →PLURPluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel
HAIFA, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease tre
Read more →PLURPluristem to Present at the International Congress of Radiation Research and Chair Two Panels at the Annual Meeting of the International Society for Cellular Therapy
HAIFA, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced participation at two important conferences: International Congress of Radiation Research Location:
Read more →PLURPluristem to Conduct Conference at Tel Aviv Stock Exchange to Review Regulatory Progress and Company Strategy
HAIFA, Israel, May 19, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced it will conduct a conference on Monday, May 25, 2015 at 8:30 AM, at the Tel Aviv Stock Exchange's co
Read more →PLURPluristem's PLX Cells One Step Closer to Entering Japan's Accelerated Pathway for Regenerative Medicine
HAIFA, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) agreed with the proposed quality and
Read more →PLURPluristem to Hold Symposium on Therapeutic Angiogenesis for Peripheral Arterial Occlusive Disease at European Society for Vascular Medicine in Berlin, Germany
HAIFA, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that on May 12 it will hold a symposium on therapeutic angiogenesis for Peripheral Arterial Occlusive
Read more →PLURPluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow
HAIFA, Israel, May 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled "Methods for Cell Expansion and Uses of Cells
Read more →PLURPluristem to Present at Five Industry and Finance Conferences in May
HAIFA, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its executives will present at the following regenerative medicine and finance conferences durin
Read more →PLURPluristem's Clinical Advisory Board Prepares Phase II Clinical Trials in Critical Limb Ischemia in Europe and Japan
HAIFA, Israel, April 20, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that its Clinical Advisory Board for Critical Limb Ischemia (CLI) concluded a key meeting in Londo
Read more →PLURPluristem Announces Key Strategic Objectives for Development of PLX-R18 in Hematopoietic Indications
HAIFA, Israel, March 24, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced the development strategy for PLX-R18, its second cell product. Pluristem recently reported positi
Read more →PLURPluristem to Present Data at Regenerative Medicine Conferences in Japan and South Korea
HAIFA, Israel, March 9, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that members of its executive and scientific teams will present at two key regenerative medicine co
Read more →PLURPluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation
HAIFA, Israel, March 3, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow t
Read more →PLURPluristem Announces Significant New Finding From Its Phase I/II Muscle Injury Trial and Excellent Safety Profile for PLX-PAD Cells at Twelve Months
HAIFA, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapies, announced an important new finding from its Phase I/II clinical trial of PLacental eXpanded (PLX-PAD) cells in the treatmen
Read more →PLURPluristem to Present at Two Cell Therapy Conferences in January 2015
HAIFA, Israel, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:CM) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today it will be presenting at two cell therapy conferences during the month of January. Both presentations
Read more →PLURPluristem Granted Patent for Foundational Cell Harvesting Technology in South Africa
HAIFA, Israel, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. 2013/07160, titled "Methods and Systems for Harvesting Adherent S
Read more →PLURPluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
HAIFA, Israel, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusal
Read more →PLURPluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology
HAIFA, Israel, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today it has been granted a patent in Singapore titled "Methods for Cell Expansion and Uses of Cells and C
Read more →PLURPluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences
HAIFA, Israel, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Dr. Ohad Karnieli, the Company's vice president of development and manufacturing, will present
Read more →PLURPluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications
HAIFA, Israel, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has been granted a patent in both Australia and New Zealand for the use of a specified popu
Read more →PLURPluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014
London Regenerative Medicine Network Meeting Alliance for Regenerative Medicine's 2nd Annual European Advanced Therapies Investor Day HAIFA, Israel, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based ce
Read more →PLURPluristem Advances Its Second Major Cell Therapy Product Line From Development to Large-Scale Manufacturing
HAIFA, Israel, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has completed development of its second major product line, and can now begin manufacturing
Read more →PLURPluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims
HAIFA, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that its European Patent No. EP2200622, titled, "ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND
Read more →PLURPluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market
HAIFA, Israel, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today it is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded (P
Read more →PLURPluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting
HAIFA, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that the Company's Vice President of Research & Intellectual Property, Racheli Ofir, Ph.D., and it
Read more →PLURPluristem to Present at Financial Conferences in New York City on September 10th and 17th, 2014
HAIFA, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today its executives will present at two financial conferences in New York City during the month of Septe
Read more →PLURPluristem to Host Investor Breakfast and Webcast on July 23 in New York City
HAIFA, Israel, July 22, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it will host an investor breakfast on Wednesday, July 23 in New York City. Prof. Baha M. Sibai, MD, a
Read more →PLURPluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial
HAIFA, Israel, July 8, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the
Read more →PLURPluristem's Ohad Karnieli to Deliver a Plenary Presentation on Cell Therapy Manufacturing at ISUS 2014 Conference
HAIFA, Israel, June 30, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced its VP of Development & Manufacturing, Ohad Karnieli, Ph.D., will give a plenary talk at the Bio-Process S
Read more →PLURPluristem Selects Rotator Cuff Repair as New Orthopedic Indication
HAIFA, Israel, June 25, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected rotator cuff repair as the second indication in its orthopedic clinical program. The Compa
Read more →PLURPluristem Granted Patent in Russia for Treatment of Inflammatory Bowel Disease Using Placenta-Derived Cells
HAIFA, Israel, June 19, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Russia's Federal Service for Intellectual Property has granted to Pluristem Patent No. 2515156 titled
Read more →PLURPluristem Receives Patent in India for Cell Therapy Production Methods and Compositions
HAIFA, Israel, June 16, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted Patent No. 261087 from India's Office of the Controller General of Patents, Designs &
Read more →PLURPluristem to Exhibit at BIO International Convention in San Diego on June 23 - 26, 2014
HAIFA, Israel, June 10, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that it will exhibit at the BIO International Convention from June 23-26, 2014 in San Diego, California. P
Read more →PLURPluristem Move Forward in the Orthopedic Area With the Support of Key Opinion Leaders
HAIFA, Israel, May 29, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has enhanced its activity in the orthopedic indications for its PLacental eXpanded (PLX) cell therapies.
Read more →PLURPluristem to Participate in Upcoming Financial Conferences
HAIFA, Israel, May 27, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Company's COO, Yaky Yanay, and the Divisional VP for North America, Dr. Karine Kleinhaus, will par
Read more →PLURPluristem Receives Clearance From South Korea to Use PLX Cells Manufactured at Its New Facility in Its Advances Studies
HAIFA, Israel, May 20, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the latest advancement in its clinical and commercial development programs in South Korea. The South Korean
Read more →PLURPluristem to Present at World Stem Cells Regenerative Medicine Congress 2014 in London
HAIFA, Israel, May 12, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Company's CEO Zami Aberman will participate in the 9th Annual World Stem Cells Regenerative Medic
Read more →PLURPluristem to be Added to New TA Tech-Elite Stock Index in Israel
HAIFA, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its shares of common stock will be added to a newly created TA Tech-Elite index on the Tel Aviv Stock Exchange. Scheduled for launch on May 11, 2014, the TA T
Read more →PLURPluristem Awarded $4.2 Million Grant by Israeli Government
HAIFA, Israel, April 30, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $4.2 million) grant from the Office
Read more →PLURPluristem's Manufacturing Facility Approved by European Auditors for Phase III Trials
HAIFA, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its new manufacturing facility has received the European Union's Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell
Read more →PLURPluristem and the Alliance for Regenerative Medicine Advocate for Industry Advancement in Washington D.C.
HAIFA, Israel, April 22, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Company executives are actively participating in a series of meetings in Washington D.C. regarding
Read more →PLURPluristem to Deliver Key Commercialization and Scientific Presentations at International Society for Cellular Therapy Conference 2014
HAIFA, Israel, April 16, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Dr. Ohad Karnieli, Vice President of Development and Manufacturing, and Lena Pinzur, Basic and Prec
Read more →PLURPluristem Scientists to Present a Poster on GvHD & Participate in a Panel Discussion at the BIRAX Regenerative Medicine Conference
HAIFA, Israel, March 25, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced its participation in the 2nd UK-Israel Regenerative Medicine Conference (BIRAX), which is being held on
Read more →PLURPluristem to Present at Barclays and RegenMed Financial Conferences
HAIFA, Israel, March 11, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that Company executives will present at two upcoming financial conferences: Barclays Global Healthcare
Read more →PLURPluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014
HAIFA, Israel, March 7, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief Executive Officer Zami Aberman will deliver a brief presentation and be a panelist at
Read more →PLURPluristem Submits FDA Orphan Drug Application for Preeclampsia
HAIFA, Israel, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration requesting the Company
Read more →PLURPluristem Receives Key 3D Cell Expansion Patent in Australia
HAIFA, Israel, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method an
Read more →PLURPluristem CEO Zami Aberman to Speak on Panel at 9th Annual Stem Cell Summit on February 18, 2014
HAIFA, Israel, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that its CEO and Chairman, Zami Aberman, will be a speaker on a panel titled, "Disrupting the Pharma Mode
Read more →PLURPluristem Strengthens Executive Team; Announces Senior Executive Appointments
HAIFA, Israel, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the appointments of two of its senior executives. These executive appointments support the Company's growt
Read more →PLURPluristem CEO Zami Aberman to Present at Phacilitate Cell & Gene Therapy Forum 2014
HAIFA, Israel, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell product candidates, today announced the Company's Chairman and CEO, Zami Aberman, will make two presentations and speak in panel dis
Read more →PLURPluristem's Cell Manufacturing Facility Marks Major Milestone With German Regulatory Approval of New Scaled-Up 3D Manufacturing Process
HAIFA, Israel, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell product candidates, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), Germany's health authority, to s
Read more →PLURPluristem's Phase I/II Muscle Injury Trial Successfully Meets Primary Safety & Efficacy Endpoints
HAIFA, Israel, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced top-line results from its Phase I/II clinical trial testing the safety and efficacy of PLacental eXpanded
Read more →PLURPluristem Receives Key Placental Cell Therapy Patent in Australia
HAIFA, Israel, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent in Australia. Patent #2008300185, titled "Methods for Cell Expansion and
Read more →PLURPluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $10.4 Million
Pluristem issues shares to CHA at a price per share of $4.16 Development and Commercialization of PLX-PAD cells for the Treatment of Peripheral Artery Disease in South Korea HAIFA, Israel, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) t
Read more →PLURPluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
HAIFA, Israel, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the South Korean Ministry of Food and Drug Safety (MFDS), formerly the Korea Food & Drug Administrati
Read more →PLURPluristem to Present at Omics Group's 2nd International Conference and Exhibition on Cell & Gene Therapy
HAIFA, Israel, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Pluristem's VP of Development, Ohad Karnieli PhD will present at Omics Group's 2nd International Conf
Read more →PLURPluristem to Present Scientific Poster and Corporate Overview at Stem Cell Meeting on the Mesa
HAIFA, Israel, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company will be actively participating in the Stem Cell Meeting on the Mesa on October 14-16, 201
Read more →PLURPluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
HAIFA, Israel, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry of Health has approved the company's request to initiate a Phase II study using i
Read more →PLURPluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease
Both Intramuscular and Intravenous Administrations Show Statistically Significant Improvement Clinical Path Being Investigated With Leading Medical Institutions HAIFA, Israel, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading deve
Read more →PLURPluristem Granted Key U.S. Patent for the Treatment of Peripheral Artery Disease
HAIFA, Israel, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has completed a major step in its intellectual property strategy: the United States Pate
Read more →PLURPluristem Awarded a $3.3 Million Grant by Israeli Government
HAIFA, Israel, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 12 million New Israeli Shekels (approximately $3.3 million) grant from the Office of
Read more →PLURPluristem Completes Enrollment for Phase I/II Muscle Injury Trial
HAIFA, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has completed the target enrollment in a randomized, double-blinded, placebo controlled Phase I/II clin
Read more →PLURPluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
HAIFA, Israel, July 8, 2013 (GLOBE NEWSWIRE) -- On the heels of announcing its strategic partnership agreement with Cha Bio&Diostech (Kosdaq:CHA) on June 26th, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced t
Read more →PLURPluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercialization of PLX Cells for the Treatment of CLI and IC in South Korea
HAIFA, Israel, June 26, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license and strategic partnership agreement with Cha Bio&Diostech (Kosdaq:CHA
Read more →PLURPluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONE
HAIFA, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that preclinical results for its Placental eXpanded (PLX) RAD cells in the treatment of bone marrow diseas
Read more →PLURPluristem Provides Update on Clinical Status of IC Trials
HAIFA, Israel, June 19, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, provided an update today on the status of its clinical trials in Intermittent Claudication (IC): As previously announced,
Read more →PLURPluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMed
HAIFA, Israel, June 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Pluristem's CEO and its Project Innovation Research Manager will be delivering two different presenta
Read more →PLURPluristem to Receive Clinical-hold Notice From the U.S. FDA
HAIFA, Israel, June 4, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that its United States p
Read more →PLURPluristem to Present at FDA Symposium
HAIFA, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has been invited to present at the U.S. Food & Drug Administration's (FDA) Medical Counter
Read more →PLURPluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and Nuclear Safety and the Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies
HAIFA, Israel, May 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Katherina Reiche, Parliamentary State Secretary of the German Federal Ministry for Environmental, Natu
Read more →PLURPluristem Develops PLX-RAD Cells for Use in Hematology
HAIFA, Israel, May 7, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has identified its first clinical indication in the hematology field for its Placental eXpanded (PLX
Read more →PLURPluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013
HAIFA, Israel, April 30, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the company is scheduled to participate in the following investment conferences in May 2013: Event: 12 t
Read more →PLURPluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine
HAIFA, Israel, April 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it is expanding its presence in the orthopedic and sports medicine markets with plans to initiate a Phase
Read more →PLURPluristem Announces Scientific and Investment Conferences for April 2013
HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled to participate in several scientific and investment conferences in April 2013. T
Read more →PLURPluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury
HAIFA, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today reported on the progress of its ongoing double blind Phase I/II clinical trial to test the safety and efficacy of i
Read more →PLURPluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has designated Pluristem's PLacental eXpanded (PLX) cells
Read more →PLURPluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13
HAIFA, Israel, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Zami Aberman, Chairman and Chief Executive Officer of Pluristem, will participate in a roundtable dis
Read more →PLURPluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing Facility
HAIFA, Israel, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has taken possession of and is moving into its new state-of-the-art GMP facility. The fa
Read more →PLURPluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference
HAIFA, Israel, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Senior Scientists at Pluristem will be presenting updated developments relating to the company's pro
Read more →PLURPluristem Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany
HAIFA, Israel, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapies, announced today that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products fo
Read more →PLURPluristem's CEO Letter to Shareholders
HAIFA, Israel, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Dear Pluristem Shareholders, In 2012 we have made great progress and moved closer to fulfilling our vision of being a leader in developing and manufacturing cell therapies. We have had significant achievements in many areas includ
Read more →PLURPluristem Initiates Final Validation of New Manufacturing Facility
HAIFA, Israel, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has initiated the final validation steps for its new "state-of-the-art" manufacturing facility prior t
Read more →PLURPluristem to Present at Oppenheimer 23rd Annual Healthcare Conference
HAIFA, Israel, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that William R. Prather RPh, MD, Senior VP Corporate Development, will present at the Oppenheimer 23rd Annual Healthcare Conference at the Waldorf Astoria in Ne
Read more →PLURPluristem Joins Both the TA-75 and TA-100 Indexes on the Tel Aviv Stock Exchange
HAIFA, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has been informed by the Tel Aviv Stock Exchange (TASE) that its shares are now listed in both the Tel
Read more →PLURPluristem Advances Its Intramuscular Hematology Program; Assembles Clinical Advisory Board of World Renowned Opinion Leaders
HAIFA, Israel, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Company has established its Clinical Advisory Board (CAB) in hematology. The CAB includes prestig
Read more →PLURPluristem Reports Status of Orphan Drug Application for Aplastic Anemia
HAIFA, Israel, Nov. 21, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has updated the Company on its application to designate
Read more →PLURPluristem to Initiate a Phase I/II Clinical Trial in Muscle Injury
HAIFA, Israel, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has initiated a Phase I/II clinical trial to evaluate the safety and efficacy of its PLacental Expande
Read more →PLURPluristem Comments on Article Published on Bloomberg
HAIFA, Israel, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, offered comments on an article published in Bloomberg on November 7, 2012. Pluristem has submitted a direct request to Blo
Read more →PLURPluristem Completes Large Scale Cell Therapy Formulation for Commercial and Clinical Trial Use
HAIFA, Israel, Nov. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company has successfully completed the integration and testing of its new scaled-up formulation and man
Read more →PLURPluristem Achieves Milestone Towards Completion of Its New GMP Manufacturing Facility for Commercial Production of PLX Cells
HAIFA, Israel, Oct. 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today a milestone in the build-out of its new clinical Good Manufacturing Process (cGMP) manufacturing facility
Read more →PLURPluristem's PLX Cells Reduce Fibrotic Processes
Potential to Address Multi-Billion Markets Where Fibrosis is End Stage of Inflammatory Process Data to be Presented at the Israel Society for Placenta Research Conference HAIFA, Israel, Oct. 17, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a l
Read more →PLURPluristem Issues Letter to Shareholders Highlighting Significant Achievements on Several Fronts
HAIFA, Israel, Oct. 9, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that the Company has issued a letter to shareholders that provides an overview of the numerous milestones r
Read more →PLURPluristem Develops Point-of-Care Thawing Device for PLX Cells
HAIFA, Israel, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that a portable, compact, on-site instrument has been developed by the company for the rapid, uniform thawi
Read more →PLURPluristem Selects Fisher BioServices as Worldwide Dispatch Distributor of Its PLX Cell Therapies to Serve Global Clinical Studies
HAIFA, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected Fisher BioServices, Inc. as worldwide dispatch distributor of its off-the-shelf PLacenta
Read more →PLURPluristem Announces Closing of Underwriters' Option to Purchase Additional Common Stock
HAIFA, Israel, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced the closing of the exercise in full of the underwriters' option to purchase an additional 1,200,000 shares of common stock of the company. As previously announ
Read more →PLURPluristem Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
HAIFA, Israel, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced the closing of its previously announced firm commitment underwritten public offering of 8,000,000 units, at a purchase price of $4.00 per unit, with each unit c
Read more →PLURPluristem Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
HAIFA, Israel, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company's common stock and one war
Read more →PLURPluristem Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
HAIFA, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer shares of its common stock and warrants to purchase shares of its common stock in a registered
Read more →PLURPluristem Files for Orphan Drug Status With U.S. FDA for Use of PLX Cells in Treatment of Aplastic Anemia
HAIFA, Israel, Aug. 30, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced that it has filed the necessary documents requesting that the U.S. Food and Drug Administration (FDA) gra
Read more →PLURPluristem Commences U.S. FDA Phase II Clinical Trial for Intermittent Claudication
HAIFA, Israel, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it will initiate Phase II clinical trials in the United States in the first week of September 2012 to eva
Read more →PLURPluristem and World Renowned Charite Berlin-Brandenburg Center for Regenerative Therapies Renew Five-Year Collaborative Research Agreement
HAIFA, Israel, Aug. 21, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has renewed a five-year Collaborative Research Agreement with the Berlin-Brandenburg Center for Regene
Read more →PLURPluristem Receives Approval From Indian Ministry of Health for Use of PLX Cells in Phase II Trial for Treatment of Buerger's Disease
HAIFA, Israel, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has received permission from the Indian Ministry of Health to proceed with a Phase II clinical tr
Read more →PLURPluristem Moves Intermittent Claudication Indication Forward in Europe Through Collaboration With Cato Research
HAIFA, Israel, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has selected Cato Research as its contract research organization (CRO) for the German portion of the C
Read more →PLURPluristem Receives Approval to Commence a Phase I/II Study for Muscle Regeneration in Germany
HAIFA, Israel, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body in Germany, to
Read more →PLURPluristem's PLX Cells Show Efficacy in Treating Lung Disease
HAIFA, Israel, July 31, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in red
Read more →PLURPluristem Therapeutics Set to Enter Bone Marrow Disease Market as it is Preparing to Apply for Orphan Drug Status With the FDA for the Treatment of Aplastic Bone Marrow
HAIFA, Israel, July 23, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it is preparing to apply to the U.S. Food and Drug Administration for approval of its PLacental eXpanded
Read more →PLURPluristem Partners With CPC Clinical Research for Peripheral Artery Disease Study
HAIFA, Israel, July 18, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered i
Read more →PLURPluristem Therapeutics' Cell Therapy Broadens Addressable Markets - Demonstrates Systemic Effectiveness of Intramuscular Delivery
HAIFA, Israel, June 19, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today at the 2012 Bio International Convention the results of a pre clinical study it conducted measuring the effectiveness of its Placental eXpanded (PLX) cells when
Read more →PLURPluristem to Present at Jefferies Global Healthcare Conference
HAIFA, Israel, June 5, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that William Prather RPh, MD, Sr. VP of Corporate Development, will present at the Jefferies Global Healthcare Conference taking place June 4 - 7, 2012 in New Yo
Read more →PLURPluristem Awarded a $3.1 Million Grant by Israeli Government
HAIFA, Israel, April 30, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 11.8 million New Israeli Shekels (approximately $3.1 million) grant from the Offic
Read more →PLURPluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication
HAIFA, Israel, April 17, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), announced today that the United States Food and Drug Administration (FDA) has granted the company clearance to start a Phase II clinical trial using the company's PLX-PAD cel
Read more →PLURPluristem Forms Peripheral Artery Disease Steering Committee
HAIFA, Israel, April 3, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that it has formed a steering committee to assist in advancing PLacental eXpanded (PLX) cell therapies for the treatment of Peripheral Artery Disease (PAD). The
Read more →PLURPluristem Therapeutics to Present at Three Conferences in April
HAIFA, Israel, March 26, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that William Prather R.Ph., MD, Sr. VP of Corporate Development, will present at three upcoming financial and scientific events in the U.S. In addition to outl
Read more →PLURPluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction (AMI) in Animal Trial
HAIFA, Israel, March 20, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its PLacental eXpanded (PLX) cells, tested in a preclinical animal model of acute myocardial infarction (AMI), proved to effectively improve several cardi
Read more →PLURPluristem Begins Up Scaling Its PLX Cell Bioreactors
HAIFA, Israel, March 12, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that it has initiated the process of scaling up the Company's manufacturing bioreactors from their current size of 5 liter (L) to 15L. The up scaling process i
Read more →PLURPluristem Therapeutics' CEO Quarterly Update
HAIFA, Israel, Feb. 29, 2012 (GLOBE NEWSWIRE) -- We at Pluristem have been very busy during the last few quarters in exploiting our unique competitive position in being the only company with the ability to manufacture mass quantities of cells in a three dimensional manner. This
Read more →PLURPluristem to Expand Research & Development of Radiation Exposure Treatment
HAIFA, Israel, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that following preliminary discussions with several governmental authorities, it will expand its research and development efforts on an acute radiation exposure
Read more →PLURPluristem Awarded a $2.4 Million Grant From Israeli Government
HAIFA, Israel, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a NIS 9 million (approximately $2.4 million) grant from the Office of the Chief Sci
Read more →PLURPluristem Therapeutics' CEO Letter to Shareholders
HAIFA, Israel, Nov. 22, 2011 (GLOBE NEWSWIRE) -- As we close in on the end of the calendar year, it is important to look back upon all that we at Pluristem have accomplished over the last 12 months, but it is even more crucial to focus the majority of our energies on the challen
Read more →PLURPluristem Announces Positive 12-Month Data From the Use of PLX-PAD for the Treatment of Critical Limb Ischemia
HAIFA, Israel, Nov. 3, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced positive 12-month data from its Phase I open-label, dose-escalation clinical trials conducted under protocols approved by the Food & Drug Administration (FDA) in
Read more →PLURPluristem's PLX Cells Found to Have Potential to Treat Acute Radiation Syndrome
HAIFA, Israel, Sept. 7, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that animal studies it has conducted suggest that its PLacental eXpanded (PLX) cells are potentially effective in treating life threatening hematopoietic complic
Read more →PLURPluristem Therapeutics to Present at Leading U.S. Industry Conferences
HAIFA, Israel, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that Company executives will be presenting at five leading scientific and financial events in the U.S. during the month of September. The presentations will foc
Read more →PLURPluristem's PLX Cells Receive Orphan Drug Status for Treatment of Buerger's Disease
HAIFA, Israel, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that on August 22, 2011, the U.S. Food and Drug Administration (FDA) designated Pluristem's PLX cells orphan status for the treatment of thromboangiitis obliter
Read more →PLURPluristem Announces Effectiveness of the Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension
HAIFA, Israel, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that following the consent of the Office of the Chief Scientist of Israel, Pluristem's exclusive out-license agreement signed on June 19, 2011 with United Therape
Read more →PLURPluristem Therapeutics to Expand Manufacturing With New GMP Facility Capable of an Annual Production Capacity of Over $1 Billion
HAIFA, Israel, July 26, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), announced today that its wholly owned Israeli subsidiary, Pluristem Ltd., has entered into an agreement with MTM - Scientific Industries Center Haifa Ltd., for the leasing and
Read more →PLURPluristem and United Therapeutics Enter Into an Exclusive License Agreement to Develop and Commercialize PLX Cells for the Treatment of Pulmonary Hypertension
HAIFA, Israel, June 20, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license agreement with United Therapeutics Corporation (Nasdaq:UTHR) for the
Read more →PLURPluristem Therapeutics to Present at Upcoming Industry Conferences
HAIFA, Israel, May 5, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR), announced today that over the next two months, company executives will be presenting at four leading industry events. The presentations follow the completion of six-mo
Read more →PLURPluristem Announces Encouraging Six-Month Follow-Up Results of Its Phase I Critical Limb Ischemia Clinical Trials
HAIFA, Israel, April 13, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), today announced that following completion of three and six month clinical follow-up, data from its two open-label, dose-escalation, Phase I clinical trials conducted in the US
Read more →PLURPluristem Therapeutics to Expand Testing of PLX Cells for the Treatment of Radiation Exposure
HAIFA, Israel, April 6, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it has signed a collaborative agreement with the Hadassah University Medical Center to continue previously conducted animal study that indicates PLX cells
Read more →PLURPluristem Therapeutics and NYU Medical Center Partner to Study Use of PLX Cells in Treatment of Diabetic Foot Ulcers
HAIFA, Israel, March 15, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem's proprietary placenta-derived PLX cells for the trea
Read more →PLURPluristem Therapeutics to Present at Leading Investor Conferences
HAIFA, Israel, March 7, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (DAX:PJT) (TASE:PLTR) announced today that over the next month, company executives will present at three leading financial events. The presentations follow the recent announcement of posit
Read more →PLURPluristem on Track to Proceed to a Phase II/III Clinical Trial in Critical Limb Ischemia (CLI) Under a Joint FDA-EMA Protocol, and a Phase II Clinical Trial in Intermittent Claudication (IC)
HAIFA, Israel, Jan. 18, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) reg
Read more →PLURPluristem Therapeutics Approved for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Company Anticipates Joining four of TASE's Indexes Pluristem will open trading on the TASE on December 19 and will host a welcoming ceremony for investors and a press conference for journalists following the market opening HAIFA, Israel, Dec. 12, 2010 (GLOBE NEWSWIRE) -- Pluris
Read more →PLURPluristem to Present at the Commercial Translation of Regenerative Medicine Conference
HAIFA, Israel, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today reported that the company will present two key aspects of its clinical trials -- quality and regulatory, at the Commercial Translation of Regenerative Medicine Conference in
Read more →PLURPluristem Therapeutics Announces Interim Top-Line Results From PLX-PAD Clinical Trials
HAIFA, Israel, April 27, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemi
Read more →PLURPluristem Therapeutics Raises $2.7 Million in Private Placement of Restricted Common Stock
HAIFA, Israel, April 27, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has entered into definitive agreements with selected investors to sell restricted common stock and warrants for aggregate gross proceeds of approximately
Read more →PLURPluristem Therapeutics Granted European Union Patent for PluriX(TM) Three-Dimensional (3D) Bioreactor System
HAIFA, Israel, March 23, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has been granted a European Patent on its core 3D cell expansion technology. The granting of the European patent follows the issuance of several correspon
Read more →PLURPluristem to Present at the ROTH 22nd Annual OC Growth Conference
HAIFA, Israel, March 9, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced its participation in the Roth 22nd Annual OC Growth Conference to be held at The Ritz-Carlton in Laguna Niguel, CA, March 15-17. William R. Prather RPh, MD, Senior
Read more →PLURPluristem Therapeutics Receives DSMB Approval to Advance to Final Dose Level With PLX-PAD
HAIFA, Israel, March 2, 2010 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has received approval from an independent Data Safety Monitoring Board (DSMB) to advance to the highest and final dose level with its placenta-derived cell
Read more →PLURPluristem Therapeutics Completes Dosing of First Group of Patients in Europe With Placenta-Derived Cell Therapy Product PLX-PAD in Phase I Clinical Trial for Treatment of Critical Limb Ischemia (CLI)
HAIFA, Israel, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has completed dosing of the first of three dosage groups of patients in Europe with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-es
Read more →PLURPluristem Provides Disclosure Pursuant to NASDAQ Marketplace Rule 5250(b)(2)
HAIFA, Israel, Oct. 1, 2009 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced, that on September 23, 2009, it filed its Annual Report on Form 10-K with the SEC, which included an audit report by the company's independent registered public acc
Read more →PLURPluristem Therapeutics Approved for Listing on NASDAQ Capital Market Company's common stock will begin trading on
Therapeutics Approved for Listing on NASDAQ Capital Market common stock will begin trading on December 10, 2007(and not December 11, 2007 as previously announced) YORK-- (BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB: PSTI.OB - DAX: a leading bio-therapeutics company ded
Read more →PLURPluristem's Reverse Stock Split Effective Today Stock to Trade Under the New Symbol PSTI NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB:PSTI.OB) (DAX:PJT), a bio-therapeutics Company dedicated to the comme
Reverse Stock Split Effective Today to Trade Under the New Symbol PSTI YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB:PSTI.OB) (DAX:PJT), bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variet
Read more →PLURPluristem Announces a Reverse Stock Split in Conjunction with Its Application for Listing on the NASDAQ Capital Market NEW YORK-- (BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS .OB - DAX: PJT), a bio-therapeu
Announces a Reverse Stock Split in Conjunction with Its Application for Listing on the NASDAQ Capital Market YORK-- (BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS.OB DAX: PJT), a bio-therapeutics Company dedicated to the commercialization of non-personalized (allog
Read more →PLURPLURISTEM LIFE SYSTEMS, INC. AMENDED 2005 STOCK OPTION PLAN This Amended 2005 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Pluristem Li
PLURISTEM LIFE SYSTEMS, INC. AMENDED 2005 STOCK OPTION PLAN This Amended 2005 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Pluristem Life Systems, Inc., a corporation formed under the laws of t
Read more →PLURPluristem Announces Private Equity Investment of $8M New York
Pluristem Announces Private Equity Investment of $8M New York February 14, 2007--Pluristem Life Systems, Inc. (OTCBB: PLRS), a cell therapy Company dedicated to the commercialization of stem cell products for a variety of indications, today announced that it has signed a binding
Read more →PLURPLURISTEM COMPLETES CONVERSION OF OUTSTANDING CONVERTIBLE DEBENTURES 98% Of the$3 Million in Convertible Debentures Issued in April 2006 Have Been Converted To Common Stock
PLURISTEM COMPLETES CONVERSION OF OUTSTANDING CONVERTIBLE DEBENTURES 98% Of the$3 Million in Convertible Debentures Issued in April 2006 Have Been Converted To Common Stock HAIFA, Israel- October 24, 2006 - Pluristem Life Systems, Inc. (OTCBB: PLRS) today announced that it has
Read more →PLURCONSULTING AGREEMENT BETWEEN BIOLOGICS CONSULTING GROUP, INC. (Hereinafter "BCG") Address: 1317 King Street Alexandria, Virginia 22314 TAX I. D. #: 84-1693476 AND PLURISTEM LIFE SYSTEMS (Hereinafter "COMPANY") Address: M
CONSULTING AGREEMENT BIOLOGICS CONSULTING GROUP, INC. (Hereinafter "BCG") Address: 1317 King Street Alexandria, Virginia 22314 TAX I. D. #: 84-1693476 PLURISTEM LIFE SYSTEMS (Hereinafter "COMPANY") Address: MATAM Advanced Technology Park Bldg. No. 20 Haifa, 31905, Israel
Read more →PLURPluristem announces closing of 7% Senior Secured Convertible Debenture Private Placement Haifa, Israel
Pluristem announces closing of 7% Senior Secured Convertible Debenture Private Placement Haifa, Israel April 4, 2006-- Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the commercialization of cell therapy products, today announced that on April 3
Read more →PLURPluristem Strengthens Business Strategy Company to Focus on Commercializing Cell Therapy Products Haifa, Israel
Pluristem Strengthens Business Strategy Company to Focus on Commercializing Cell Therapy Products Haifa, Israel - March 6, 2005-- Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the commercialization of cell therapy products, today announced that
Read more →PLURPluristem Announces Advanced Engineered Cell Graft to Improve Resurgence of the Hematopoietic Stem Cells in Bone Marrow for Cancer Patients -Pre-Clinical Animal Model Testing Underway- Haifa, Israel
Advanced Engineered Cell Graft to Improve Resurgence of the Hematopoietic Stem Cells in Bone Marrow for Cancer Patients -Pre-Clinical Animal Model Testing Underway- January 12, 2005-- Pluristem Life Systems, Inc. (OTCBB:PLRS), a biotechnology company dedicated to the commerci
Read more →PLURPluristem Appoints Arnon Nagler, M.D., MSc. to Scientific Advisory Board -Pioneer and World-Acclaimed Leader in Field of Umbilical Cord Blood, Cord Blood Banking and Stem Cell Separation and Treatme
Pluristem Appoints Arnon Nagler, M.D., MSc. to Scientific Advisory Board -Pioneer and World-Acclaimed Leader in Field of Umbilical Cord Blood, Cord Blood Banking and Stem Cell Separation and Treatment, to Bring Development Activities to Scientific and Major Pharma Communities-
Read more →PLURPluristem Announces Joint Projects Product Development and Worldwide Distributorship Agreement with Biological Industries, Ltd. - Companies Target Projected $1.7 Billion Cell Culture Market in Media
Pluristem Announces Joint Projects Product Development and Worldwide Distributorship Agreement with Biological Industries, Ltd. -Companies Target Projected $1.7 Billion Cell Culture Market in Media, Sera and Reagents, Potentially Providing Pluristem Significant Revenue- Haifa
Read more →PLURPLURISTEM BOARD APPOINTS JOHN L. BAKOS PRESIDENT U.S. Leadership by Seasoned Veteran to Provide Myriad of Opportunities Haifa, Israel
PLURISTEM BOARD APPOINTS JOHN L. BAKOS PRESIDENT U.S. Leadership by Seasoned Veteran to Provide Myriad of Opportunities Haifa, Israel - February 24, 2005 - Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the expansion of stem cells from umbilica
Read more →Competitive Position
How PLUR ranks across every disease it competes inCompetitive Position is a premium feature
See how PLUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial